Creative Medical Technology Holdings Inc CELZ

NAS: CELZ | ISIN: US22529Y3099   2/05/2025
2,000 USD (+0,50%)
(+0,50%)   2/05/2025

10 oktober 2023 · Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain · Persbericht

19 september 2023 · Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain · Persbericht

28 juni 2023 · Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements · Persbericht

12 juni 2023 · Creative Medical Technology Announces $2 Million Share Repurchase Program · Persbericht

12 juni 2023 · Creative Medical Technology Holdings Provides Corporate Update · Persbericht

9 juni 2023 · Creative Medical Technology Holdings Announces Reverse Stock Split · Persbericht

31 mei 2023 · Creative Medical Technology Holdings Announces Successful Completion of the First Phase of its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz® Immunotherapy Platform · Persbericht

22 mei 2023 · Creative Medical Technology Holdings Announces Next Milestone Achievements in ImmCelz® Platform Development · Persbericht

18 mei 2023 · Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell Line · Persbericht

12 april 2023 · Creative Medical Technology Announces Positive Top-Line Results for Type 2 Diabetes Study · Persbericht

4 april 2023 · Creative Medical Technology Holdings Announces Filing of 2022 Form 10-K and Provides Business Update · Persbericht

23 maart 2023 · Creative Medical Technology Files Orphan Drug Designation Application with the U.S. FDA Using the ImmCelz® Platform for the Treatment of Brittle Type 1 Diabetes · Persbericht

21 maart 2023 · Creative Medical Technology Holdings Announces Key Milestones Regarding ImmCelz® Platform Development · Persbericht

8 februari 2023 · Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Novel Cell Therapy for the Treatment of Type 1 Diabetes · Persbericht

3 november 2022 · Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem™, a Novel Cell Therapy for the Treatment of Type 1 Diabetes · Persbericht

20 oktober 2022 · Creative Medical Technology Holdings Develops AlloStem™ Clinical Cell Line · Persbericht

26 september 2022 · Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine® Study · Persbericht

28 juli 2022 · Creative Medical Technology Announces Positive Top-Line Results for OvaStem® Pilot Study · Persbericht

Mijn selecties